Search Results - "Clinical pharmacology and therapeutics"

An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine by Whirl‐Carrillo, Michelle, Huddart, Rachel, Gong, Li, Sangkuhl, Katrin, Thorn, Caroline F., Whaley, Ryan, Klein, Teri E.

“…Clinical annotations are one of the most popular resources available on the Pharmacogenomics Knowledgebase (PharmGKB). Each clinical annotation summarizes the…”
Get full text

Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection by Du, Yin‐Xiao, Chen, Xiao‐Ping

“…An outbreak of 2019‐nCoV infection has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID‐2019. In addition to…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy by Crews, Kristine R., Monte, Andrew A., Huddart, Rachel, Caudle, Kelly E., Kharasch, Evan D., Gaedigk, Andrea, Dunnenberger, Henry M., Leeder, J. Steven, Callaghan, John T., Samer, Caroline Flora, Klein, Teri E., Haidar, Cyrine E., Van Driest, Sara L., Ruano, Gualberto, Sangkuhl, Katrin, Cavallari, Larisa H., Müller, Daniel J., Prows, Cynthia A., Nagy, Mohamed, Somogyi, Andrew A., Skaar, Todd C.

“…Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone,…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update by Johnson, JA, Caudle, KE, Gong, L, Whirl‐Carrillo, M, Stein, CM, Scott, SA, Lee, MT, Gage, BF, Kimmel, SE, Perera, MA, Anderson, JL, Pirmohamed, M, Klein, TE, Limdi, NA, Cavallari, LH, Wadelius, M

“…This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update by Amstutz, Ursula, Henricks, Linda M., Offer, Steven M., Barbarino, Julia, Schellens, Jan H.M., Swen, Jesse J., Klein, Teri E., McLeod, Howard L., Caudle, Kelly E., Diasio, Robert B., Schwab, Matthias

“…The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the…”
Get full text

Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing Projects by Zhou, Y, Ingelman‐Sundberg, M, Lauschke, VM

“…Genetic polymorphisms in cytochrome P450 (CYP) genes can result in altered metabolic activity toward a plethora of clinically important medications. Thus,…”
Get full text

An Introduction to Machine Learning by Badillo, Solveig, Banfai, Balazs, Birzele, Fabian, Davydov, Iakov I., Hutchinson, Lucy, Kam‐Thong, Tony, Siebourg‐Polster, Juliane, Steiert, Bernhard, Zhang, Jitao David

“…In the last few years, machine learning (ML) and artificial intelligence have seen a new wave of publicity fueled by the huge and ever‐increasing amount of…”
Get full text

The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database by Gaedigk, Andrea, Ingelman‐Sundberg, Magnus, Miller, Neil A., Leeder, J. Steven, Whirl‐Carrillo, Michelle, Klein, Teri E.

“…The Human Cytochrome P450 (CYP) Allele Nomenclature Database, a critical resource for the pharmacogenetics and genomics communities, has transitioned to the…”
Get full text

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective by Shebley, Mohamad, Sandhu, Punam, Emami Riedmaier, Arian, Jamei, Masoud, Narayanan, Rangaraj, Patel, Aarti, Peters, Sheila Annie, Reddy, Venkatesh Pilla, Zheng, Ming, Zwart, Loeckie, Beneton, Maud, Bouzom, Francois, Chen, Jun, Chen, Yuan, Cleary, Yumi, Collins, Christiane, Dickinson, Gemma L., Djebli, Nassim, Einolf, Heidi J., Gardner, Iain, Huth, Felix, Kazmi, Faraz, Khalil, Feras, Lin, Jing, Odinecs, Aleksandrs, Patel, Chirag, Rong, Haojing, Schuck, Edgar, Sharma, Pradeep, Wu, Shu‐Pei, Xu, Yang, Yamazaki, Shinji, Yoshida, Kenta, Rowland, Malcolm

“…This work provides a perspective on the qualification and verification of physiologically based pharmacokinetic (PBPK) platforms/models intended for regulatory…”
Get full text

From Real‐World Patient Data to Individualized Treatment Effects Using Machine Learning: Current and Future Methods to Address Underlying Challenges by Bica, Ioana, Alaa, Ahmed M., Lambert, Craig, Schaar, Mihaela

“…Clinical decision making needs to be supported by evidence that treatments are beneficial to individual patients. Although randomized control trials (RCTs) are…”
Get full text

Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe by Cave, Alison, Kurz, Xavier, Arlett, Peter

Get full text

PharmVar GeneFocus: CYP2D6 by Nofziger, Charity, Turner, Amy J., Sangkuhl, Katrin, Whirl‐Carrillo, Michelle, Agúndez, José A.G., Black, John L., Dunnenberger, Henry M., Ruano, Gualberto, Kennedy, Martin A., Phillips, Michael S., Hachad, Houda, Klein, Teri E., Gaedigk, Andrea

“…The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the…”
Get full text

Primary Human Lung Alveolus‐on‐a‐chip Model of Intravascular Thrombosis for Assessment of Therapeutics by Jain, A, Barrile, R, van der Meer, AD, Mammoto, A, Mammoto, T, Ceunynck, K, Aisiku, O, Otieno, MA, Louden, CS, Hamilton, GA, Flaumenhaft, R, Ingber, DE

“…Pulmonary thrombosis is a significant cause of patient mortality; however, there are no effective in vitro models of thrombi formation in human lung…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy by Moriyama, B, Obeng, A Owusu, Barbarino, J, Penzak, SR, Henning, SA, Scott, SA, Agúndez, JAG, Wingard, JR, McLeod, HL, Klein, TE, Cross, SJ, Caudle, KE, Walsh, TJ

“…Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update by Phillips, Elizabeth J., Sukasem, Chonlaphat, Whirl‐Carrillo, Michelle, Müller, Daniel J., Dunnenberger, Henry M., Chantratita, Wasun, Goldspiel, Barry, Chen, Yuan‐Tsong, Carleton, Bruce C., George, Alfred L., Mushiroda, Taisei, Klein, Teri, Gammal, Roseann S., Pirmohamed, Munir

“…The variant allele HLA‐B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy by Brown, Jacob T., Bishop, Jeffrey R., Sangkuhl, Katrin, Nurmi, Erika L., Mueller, Daniel J., Dinh, Jean C., Gaedigk, Andrea, Klein, Teri E., Caudle, Kelly E., McCracken, James T., Leon, Jose, Leeder, J. Steven

“…Atomoxetine is a nonstimulant medication used to treat attention‐deficit/hyperactivity disorder (ADHD). Cytochrome P450 (CYP)2D6 polymorphisms influence the…”
Get full text

Pharmacogenomics Knowledge for Personalized Medicine by Whirl-Carrillo, M, McDonagh, E M, Hebert, J M, Gong, L, Sangkuhl, K, Thorn, C F, Altman, R B, Klein, T E

“…The Pharmacogenomics Knowledgebase (PharmGKB) is a resource that collects, curates, and disseminates information about the impact of human genetic variation on…”
Get full text

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology by Verheijen, Remy B., Yu, Huixin, Schellens, Jan H.M., Beijnen, Jos H., Steeghs, Neeltje, Huitema, Alwin D.R.

“…Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update by Crews, K R, Gaedigk, A, Dunnenberger, H M, Leeder, J S, Klein, T E, Caudle, K E, Haidar, C E, Shen, D D, Callaghan, J T, Sadhasivam, S, Prows, C A, Kharasch, E D, Skaar, T C

“…Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update by Karnes, Jason H., Rettie, Allan E., Somogyi, Andrew A., Huddart, Rachel, Fohner, Alison E., Formea, Christine M., Ta Michael Lee, Ming, Llerena, Adrian, Whirl‐Carrillo, Michelle, Klein, Teri E., Phillips, Elizabeth J., Mintzer, Scott, Gaedigk, Andrea, Caudle, Kelly E., Callaghan, John T.

“…Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in…”
Get full text